Affiliation:
1. “Prof. Dr. George I.M. Georgescu” Institute of Cardiovascular Diseases , Iaşi , Romania
2. “Grigore T. Popa” University of Medicine and Pharmacy , Iaşi , Romania
Abstract
Abstract
Left ventricular assist device (LVAD) has emerged as a safe, durable, and revolutionary therapy for end-stage heart failure patients. Despite the appearance of newer-generation devices that have improved patient outcomes, the burden of adverse events remains significant. Although the survival rate for patients with LVAD is appreciated to be 81% at 1 year and 70% at 2 years, the incidence of adverse events is also high. Over time, both early and late postimplant complications have diminished in terms of prevalence and impact; however, complications, such as infections, bleeding, right heart failure, pump thrombosis, aortic insufficiency, or stroke, continue to represent a challenge for the practitioner. Therefore, the aim of this review is to highlight the most recent data regarding the current use of LVAD in the treatment of end-stage heart failure, with a specific focus on LVAD-related complications, in order to improve device-related outcomes. It will also revise how to mitigate the risk and how to approach specific adverse events. Withal, understanding the predisposing risk factors associated with postimplant complications, early recognition and appropriate treatment help to significantly improve the prognosis for patients with end-stage heart failure.
Reference67 articles.
1. 1. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123-1133. doi: 10.1016/j.jacc.2013.11.053.10.1016/j.jacc.2013.11.053
2. 2. Lahoz R, Fagan A, McSharry M, Proudfoot C, Corda S, Studer R. Recurrent heart failure hospitalizations are associated with increased cardiovascular mortality in patients with heart failure in Clinical Practice Research Datalink. ESC Heart Fail. 2020;10.1002/ehf2.12727. doi: 10.1002/ehf2.12727.10.1002/ehf2.12727
3. 3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-239. doi: 10.1161/CIR.0b013e31829e8807.10.1161/CIR.0b013e31829e8807
4. 4. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215. doi: 10.1161/CIRCULATIONAHA.109.192667.10.1161/CIRCULATIONAHA.109.192667
5. 5. Guglin M, Zucker MJ, Borlaug BA, et al. Evaluation for heart transplantation and LVAD Implantation: JACC council perspectives. J Am Coll Cardiol. 2020;75:1471-1487. doi: 10.1016/j.jacc.2020.01.034.10.1016/j.jacc.2020.01.034
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献